DrugTrek is a micro small-to-medium enterprise (SME) and a Fleming and Uni-Pharma spinoff founded in 2025. DrugTrek was created following years of collaboration between the BSRC Fleming, a leading Research Institute in Greece, and UniPharma, one of the largest pharmaceutical companies in Greece. Their collaborative research and development on Autotaxin and small-molecule inhibitors have led to an extensive intellectual property (IP) portfolio and to EL244, a promising clinical candidate for the treatment of IPF and other ILDs, an unmet medical need. DrugTreks’ ambition is to bring EL244 to the clinic and alleviate the heavy societal toll of fibrosis, while exploiting the momentum of the IPF financial ecosystem and commercializing the related IP.
DrugTrek abide by national and European regulations that ensure transparency, the prevention of all forms of discrimination, accessibility for persons with disabilities, gender equality (as reflected in the Gender Equality Plan, that has been adopted from Fleming) and considers the Charter of Fundamental Rights of the European Union, the principle of sustainable development, and the Union’s environmental policy, in accordance with Articles 11 and 191(1) of the TFEU. DrugTrek follows an Equal Opportunities recruitment policy, hiring qualified personnel regardless of their racial or ethnic origin, gender, religion, beliefs, disability, age, gender identity, or sexual orientation.
